Related Experiment Videos
[Target range of PTH in ESRD patients]
Takashi Shigematsu1, Hitomi Kawamura, Keita Hirano
1Department of medicine, Division of Nephrology & hypertension Director of Nephrology and Dialysis Unit, Aoto General hospital Jikei University School of Medicine.
Clinical Calcium
|March 19, 2005
Summary
Maintaining normal bone turnover is crucial for ESRD patients. This study recommends a target intact parathyroid hormone (PTH) range of 100-150 pg/mL for optimal bone health and patient survival.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Context:
- Bone turnover is vital for End-Stage Renal Disease (ESRD) patients, impacting skeletal health, quality of life (QOL), and survival.
- Abnormal bone turnover in ESRD can lead to renal osteodystrophy and ectopic calcification.
- Parathyroid hormone (PTH) is a primary regulator of bone turnover.
Purpose:
- To establish a target zone for intact parathyroid hormone (PTH) levels in ESRD patients with skeletal resistance to PTH.
- To provide recommended PTH ranges for maintaining normal calcium (Ca), phosphate (Pi), and bone metabolism.
Summary:
- The study recommends a target intact-PTH range of 100-150 pg/mL for ESRD patients.
- This range is equivalent to C-PTH 4.0-6.2 ng/mL, HS-PTH 10.0-16.0 ng/mL, and whole-PTH 80-110 pg/mL.
- Achieving normocalcemia and normophosphatemia is essential for reaching the target PTH zone with active vitamin D therapy.
Impact:
- Optimizing PTH levels can mitigate skeletal complications in ESRD.
- Improved bone metabolism may enhance patient quality of life and survival rates.
- This research provides a clinical guideline for managing bone turnover in ESRD patients.